MX2024002892A - Azalidos inmunomoduladores. - Google Patents
Azalidos inmunomoduladores.Info
- Publication number
- MX2024002892A MX2024002892A MX2024002892A MX2024002892A MX2024002892A MX 2024002892 A MX2024002892 A MX 2024002892A MX 2024002892 A MX2024002892 A MX 2024002892A MX 2024002892 A MX2024002892 A MX 2024002892A MX 2024002892 A MX2024002892 A MX 2024002892A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- immunomodulating
- formula
- azalides
- disorder
- Prior art date
Links
- 230000002519 immonomodulatory effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000026278 immune system disease Diseases 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 230000002757 inflammatory effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se definen en la presente compuestos inmunomoduladores de la Fórmula (1), en donde R, R0, R1, R2 (ver Fórmula) y W son como se definen en la presente, estereoisómeros de estos, y sales aceptables desde el punto de vista farmacéutico de estos; y composiciones que comprenden dichos compuestos. La invención también incluye métodos para tratar o prevenir una enfermedad o trastorno inflamatorio y/o inmunológico en un animal al administrar una cantidad terapéuticamente eficaz de un compuesto de la Fórmula (1), un estereoisómero de este o una sal aceptable desde el punto de vista farmacéutico de este; o el uso de dicho compuesto de la Fórmula (1) para preparar un medicamento para tratar o prevenir una enfermedad o trastorno inflamatorio y/o inmunológico en un animal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163241126P | 2021-09-07 | 2021-09-07 | |
| PCT/US2022/042421 WO2023038852A1 (en) | 2021-09-07 | 2022-09-02 | Immunomodulating azalides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024002892A true MX2024002892A (es) | 2024-04-05 |
Family
ID=83457385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024002892A MX2024002892A (es) | 2021-09-07 | 2022-09-02 | Azalidos inmunomoduladores. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12378233B2 (es) |
| EP (1) | EP4399216B1 (es) |
| JP (1) | JP7770547B2 (es) |
| KR (1) | KR20240056746A (es) |
| CN (1) | CN118139870A (es) |
| AU (1) | AU2022343476B2 (es) |
| CA (1) | CA3231535A1 (es) |
| CL (1) | CL2024000657A1 (es) |
| CO (1) | CO2024002712A2 (es) |
| MX (1) | MX2024002892A (es) |
| WO (1) | WO2023038852A1 (es) |
| ZA (1) | ZA202401768B (es) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2064634C (en) * | 1991-04-04 | 1998-08-04 | James V. Heck | 9-deoxo-8a-aza-8a-homoerythromycin a derivatives modified at the 4"- and8a-positions |
| US5985844A (en) | 1992-03-26 | 1999-11-16 | Merck & Co., Inc. | Homoerythromycin A derivatives modified at the 4"-and 8A-positions |
| US5215980A (en) * | 1992-01-17 | 1993-06-01 | Merck & Co., Inc. | 10-AZA-9-deoxo-11-deoxy-erythromycin A and derivatives thereof |
| AU779748C (en) | 2000-01-27 | 2005-12-08 | Zoetis Services Llc | Azalide antibiotic compositions |
| EA200200995A1 (ru) | 2000-04-27 | 2003-04-24 | Пфайзер Продактс Инк. | Применение композиций азалидных антибиотиков для лечения или предупреждения бактериальных или протозойных инфекций у млекопитающих |
| KR20040066186A (ko) * | 2000-08-17 | 2004-07-23 | 샤단호칭키타사토겐큐쇼 | 신규 슈도에리쓰로마이신 유도체 |
| ITMI20022292A1 (it) | 2002-10-29 | 2004-04-30 | Zambon Spa | 9a-azalidi ad attivita' antiinfiammatoria. |
| ITMI20040124A1 (it) * | 2004-01-29 | 2004-04-29 | Zambon Spa | Macrolidi ad attivita' antiinfiammatoria |
| WO2009023196A1 (en) * | 2007-08-10 | 2009-02-19 | Y's Therapeutics Co, Ltd. | Modulation of immune responses by administration of roxithromycin or its derivative |
| WO2011116312A1 (en) * | 2010-03-19 | 2011-09-22 | Catabasis Pharmaceuticals, Inc. | Fatty acid macrolide derivatives and their uses |
| US20160031925A1 (en) | 2013-04-10 | 2016-02-04 | Probiotic Pharmaceuticals Aps | Azithromycin antimicrobial derivatives with non-antibiotic pharmaceutical effect |
| GB201520419D0 (en) | 2015-11-19 | 2016-01-06 | Epi Endo Pharmaceuticals Ehf | Compounds |
| GB201608236D0 (en) * | 2016-05-11 | 2016-06-22 | Fidelta D O O | Seco macrolide compounds |
| CA3175087A1 (en) | 2020-03-12 | 2021-09-16 | Zoetis Services Llc | Immunomodulating o-het/aryl azalides |
-
2022
- 2022-09-02 AU AU2022343476A patent/AU2022343476B2/en active Active
- 2022-09-02 EP EP22777846.1A patent/EP4399216B1/en active Active
- 2022-09-02 KR KR1020247011525A patent/KR20240056746A/ko active Pending
- 2022-09-02 WO PCT/US2022/042421 patent/WO2023038852A1/en not_active Ceased
- 2022-09-02 JP JP2024515051A patent/JP7770547B2/ja active Active
- 2022-09-02 CN CN202280071098.2A patent/CN118139870A/zh active Pending
- 2022-09-02 CA CA3231535A patent/CA3231535A1/en active Pending
- 2022-09-02 MX MX2024002892A patent/MX2024002892A/es unknown
- 2022-09-06 US US17/929,777 patent/US12378233B2/en active Active
-
2024
- 2024-02-29 ZA ZA2024/01768A patent/ZA202401768B/en unknown
- 2024-03-04 CO CONC2024/0002712A patent/CO2024002712A2/es unknown
- 2024-03-05 CL CL2024000657A patent/CL2024000657A1/es unknown
-
2025
- 2025-04-08 US US19/172,798 patent/US20250236616A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240056746A (ko) | 2024-04-30 |
| ZA202401768B (en) | 2025-08-27 |
| CL2024000657A1 (es) | 2024-07-05 |
| JP7770547B2 (ja) | 2025-11-14 |
| JP2024535760A (ja) | 2024-10-02 |
| CO2024002712A2 (es) | 2024-03-27 |
| US20230129040A1 (en) | 2023-04-27 |
| AU2022343476B2 (en) | 2025-02-20 |
| CN118139870A (zh) | 2024-06-04 |
| AU2022343476A1 (en) | 2024-03-21 |
| CA3231535A1 (en) | 2023-03-16 |
| EP4399216A1 (en) | 2024-07-17 |
| US20250236616A1 (en) | 2025-07-24 |
| EP4399216B1 (en) | 2025-12-31 |
| US12378233B2 (en) | 2025-08-05 |
| WO2023038852A1 (en) | 2023-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY202837A (en) | Lipids for lipid nanoparticle delivery of active agents | |
| CR20230310A (es) | Inhibidores de prmt5 | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| MX2023000798A (es) | Peptidos funcionalizados como agentes antivirales. | |
| BR0314126A (pt) | Ligandos de amida acìclica e sulfonamida para o receptor de estrogênio | |
| PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
| MX2023001756A (es) | Peptidos funcionalizados como agentes antivirales. | |
| MX2010007375A (es) | Nuevos derivados de lupano. | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| MX2010007374A (es) | Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos. | |
| MX2022011242A (es) | Inmunomodulación de o-het/aril azálidos. | |
| PH12021552201A1 (en) | Benzodiazepine derivatives as rsv inhibitors | |
| PH12022551523A1 (en) | Cyclic compounds and methods of using same | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| MX2023013683A (es) | Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a). | |
| MX2024002409A (es) | Terapias contra el cancer. | |
| MX2025000635A (es) | Compuestos cíclicos y métodos de utilización de estos | |
| BR112022009533A2 (pt) | Composição farmacêutica para administração oral, e, método para preparar uma composição farmacêutica | |
| WO2021076938A8 (en) | Tropolone derivatives and tautomers thereof for iron regulation in animals | |
| MX2024002892A (es) | Azalidos inmunomoduladores. | |
| GEP20257771B (en) | Compounds and compositions as sppl2a inhibitors | |
| EA202193211A1 (ru) | Лечение синуклеопатий | |
| MX2023009620A (es) | Metodos terapeuticos. | |
| EP4108240A3 (en) | Benzimidazole derivatives for treatment and/or prevention of diseases and disorders mediated by nlrp3 | |
| MX2023010797A (es) | Profarmacos antivirales de entecavir (etv) y formulaciones de los mismos. |